PRME
NASDAQ · Biotechnology
Prime Medicine Inc
$2.98
+0.17 (+6.05%)
Open$2.88
Previous Close$2.81
Day High$2.98
Day Low$2.82
52W High$6.94
52W Low$2.67
Volume—
Avg Volume2.71M
Market Cap532.82M
P/E Ratio—
EPS$-1.26
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+1,349.3% upside
Current
$2.98
$2.98
Target
$43.19
$43.19
$33.60
$43.19 avg
$71.66
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.56M | 5.54M | 80.41M |
| Net Income | -241,754,345 | -327,047,779 | -21,315,556 |
| Profit Margin | -4,342.4% | -6,238.3% | -26.5% |
| EBITDA | -241,629,186 | -345,948,669 | -26,154,771 |
| Free Cash Flow | — | — | -13,660,015 |
| Rev Growth | — | -17.0% | +23.7% |
| Debt/Equity | — | — | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |